PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Drug Discovery: Solving the Structure of an Anti-hypertension Drug Target
July 2015
Retrospective: 7,000 Structures Closer to Understanding Biology
July 2015
Families in Gene Neighborhoods
June 2015
Channels and Transporters: BEST in Show
April 2015
Channels and Transporters: Reorienting a Peptide in the Pocket
April 2015
Ryanodine Receptor
April 2015
Protein Folding and Misfolding: It's the Journey, Not the Destination
March 2015
Protein Folding and Misfolding: Refolding in Membrane Mimetic
March 2015
Nuclear Pore Complex: A Flexible Transporter
February 2015
Nuclear Pore Complex: Higher Resolution of Macromolecules
February 2015
Nuclear Pore Complex: Integrative Approach to Probe Nup133
February 2015
Piecing Together the Nuclear Pore Complex
February 2015
Mitochondrion: Flipping for UCP2
December 2014
Transmembrane Spans
December 2014
Glucagon Receptor
April 2014
Membrane Proteome: A Cap on Transport
April 2014
Membrane Proteome: Microcrystals Yield Big Data
April 2014
Membrane Proteome: Pumping Out Heavy Metal
April 2014
Design and Discovery: Virtual Drug Screening
January 2014
G Proteins and Cancer
November 2013
Drug Discovery: Antidepressant Potential of 6-NQ SERT Inhibitors
October 2013
Drug Discovery: Modeling NET Interactions
October 2013
Microbiome: Solid-State NMR, Crystallized
September 2013
CAAX Endoproteases
August 2013
Membrane Proteome: A Funnel-like Viroporin
August 2013
Membrane Proteome: GPCR Substrate Recognition and Functional Selectivity
August 2013
Membrane Proteome: Making DNA Nanotubes for NMR Structure Determination
August 2013
Membrane Proteome: Unveiling the Human α-helical Membrane Proteome
August 2013
Cell-Cell Interaction: Magic Structure from Microcrystals
March 2013
Cell-Cell Interaction: Nanoparticles in Cell Camouflage
March 2013
Membrane Proteome: Capturing Multiple Conformations
December 2012
Membrane Proteome: Soft Sampling
December 2012
Membrane Proteome: Sphingolipid Synthesis Selectivity
December 2012
Membrane Proteome: Tuning Membrane Protein Expression
December 2012
Cytochrome Oxidase
November 2012
Membrane Proteome: Building a Carrier
November 2012
Membrane Proteome: Every Protein Has Its Tag
November 2012
Membrane Proteome: Specific vs. Non-specific weak interactions
November 2012
Membrane Proteome: The ABCs of Transport
November 2012
Bacterial Phosphotransferase System
October 2012
Insert Here
October 2012
Solute Channels
September 2012
To structure, faster
August 2012
Pocket changes
July 2012
Predictive protein origami
July 2012
G Protein-Coupled Receptors
May 2012
Twist to open
March 2012
Anchoring's the way
February 2012
Overexpressed problems
February 2012
Gentle membrane protein extraction
January 2012
Docking and rolling
October 2011
A fragmented approach to membrane protein structures
September 2011
Raising a glass to GLIC
August 2011
Sugar transport
June 2011
A2A Adenosine Receptor
May 2011
TrkH Potassium Ion Transporter
April 2011
Subtly different
March 2011
A new amphiphile for crystallizing membrane proteins
January 2011
CXCR4
January 2011
Guard cells pick up the SLAC
December 2010
ABA receptor diversity
November 2010
COX inhibition: Naproxen by proxy
November 2010
Zinc Transporter ZntB
July 2010
Formate transporter or channel?
March 2010
Tips for crystallizing membrane proteins in lipidic mesophases
February 2010
Urea transporter
February 2010
Five good reasons to use single protein production for membrane proteins
January 2010
Membrane proteins spotted in their native habitat
January 2010
Spot the pore
January 2010
Get3 into the groove
October 2009
GPCR subunits: Separate but not equal
September 2009
GPCR modeling: any good?
August 2009
Surviving in an acid environment
August 2009
Tips for crystallizing membrane proteins
June 2009
You look familiar: the Type VI secretion system
June 2009
Bacterial Leucine Transporter, LeuT
May 2009
Aquaglyceroporin
March 2009
Death clusters
March 2009
Protein nanopores
March 2009
Transporter mechanism in sight
February 2009
A pocket guide to GPCRs
December 2008
Tuning membrane protein overexpression
October 2008
Blocking AmtB
September 2008

Research Themes Membrane proteins

Cell-Cell Interaction: Nanoparticles in Cell Camouflage

SBKB [doi:10.1038/sbkb.2012.131]
Technical Highlight - March 2013
Short description: Membranes of white blood cells are harnessed to improve drug-delivery vehicles.

A nanoporous silicon core (a) coated with leukocyte membrane (b) can be used to create LeukoLike Vectors (c) capable of bypassing the body's surveillance. Figure courtesy of Ennio Tasciotti.

Organisms have layers of defenses against foreign attackers. But when the attack comes from within, as with cancer, clever tools are needed to evade these defenses. Hiding drugs within nanoparticles—such as nanoporous silicon (NPS)-based vehicles—has been investigated, but there is room for improvement.

To make the nanoparticles appear friendly to cells, Tasciotti and colleagues camouflaged them to resemble the organism's own white blood cells, or leukocytes. Purified negatively charged membranes and lipids effectively covered positively charged NPS, to form “leukolike vectors” (LLVs). More than half of the membranes remained bound after 24 hours in vitro. Compared to NPS particles, LLVs were protected from opsonization (tagging by antibodies or other factors that promote subsequent phagocytosis), which clears foreign objects from an organism.

Next, any vehicle injected into the bloodstream must negotiate endothelial cells lining blood vessels. With their native-cell camouflage, LLVs could pass undetected at this checkpoint. Endothelium treated with bare NPS formed filopodia, eventually expunging these particles in vesicles, but treatment with LLVs had no noticeable effect.

Finally, the vehicle must deliver the cargo to the target. LLVs contain the adhesion molecule lymphocyte function-associated antigen 1, which allows leukocytes to bind cell receptors that are upregulated in response to inflammation. True to form, LLVs exhibited twofold greater binding to inflamed versus normal endothelium, whereas NPS particles bound equally in both conditions. LLVs also have an edge in traversing the endothelium to reach cells causing the inflammation, which the researchers showed using an in vitro-reconstructed endothelial monolayer system. Only ∼30% of NPS particles could go past inflamed endothelium, whereas ∼70% of LLVs did so. When cancer cells were placed beyond the endothelial monolayer, application of a drug alone or drug-containing NPS mainly killed surface endothelial cells, whereas drug-containing LLVs decreased underlying tumor viability ∼57% and caused marginal endothelial damage.

Thus, under cover of leukocyte membranes, LLVs speak the 'cell-cell language' well enough to negotiate cell defenses en route to the target. In a proof-of-concept experiment in mice, LLVs were not found sequestered in the liver up to 40 minutes after administration, while their accumulation at tumors could be observed. With further development, LLVs may enable delivery of chemotherapeutics to cancer cells.

Irene Kaganman

References

  1. A. Parodi et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions.
    Nat. Nanotechnol. 8, 61-68 (2013). doi:10.1038/nnano.2012.212

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health